Programmed cell death protein-1 (PD-1)-targeted immunotherapy is safe and effective in patients with advanced intrahepatic cholangiocarcinoma (iCCA), according to a new retrospective analysis published in Annals of Medicine.
In a cohort of 42 patients with iCCA who received PD-1-targeted immunotherapy, the overall response rate was 23.8%, with 4 and 6 patients achieving complete and partial responses, respectively. The disease control rate was 85.7%, with 26 patients showing stable disease at follow-up radiological evaluation.
Less than half (45.2%) of the patients receiving PD-1-targeted immunotherapy showed radiological disease progression. The median time to tumor progression was 11.6 (95% CI, 7.9-15.3) months.
Twelve patients died during follow-up. The median overall survival (OS) was 19.3 (95% CI, 14.9-23.7) months, while progression-free survival (PFS) was 11.6 (95% CI, 7.9-15.3) months. Patients with progressive disease had lower median OS (3.1 vs 19.3 months) and PFS (1.9 vs 13.6 months) than patients with nonprogressive disease.
Learn about cholangiocarcinoma treatment
Moreover, patients treated with PD-1 monotherapy had a significantly shorter median OS than patients receiving combination therapy (11.6 vs 21.3), such as transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy. The median PFS was similar between the 2 groups (10.6 vs 11.5, respectively).
“From the perspective of the trend, the combined treatment has a better efficacy,” the authors said. However, they were not able to further compare combination therapies due to the small sample size.
Half of the patients experienced at least 1 adverse event, with the most common as pain (n=6), anorexia (n=4), hypertension (n=4), pyrexia (n=3), cough (n=3), and hypothyroidism (n=3). Two patients reported grade ≥3 events (pain and hepatitis). In the case of the patient who developed hepatitis, PD-1 immunotherapy was discontinued and corticosteroids were initiated.
The authors also investigated the capacity of the albumin-bilirubin (ALBI) grade to predict PD-1 immunotherapy efficacy in patients with iCCA. Patients with ALBI grade 1 had longer median OS than patients with ALBI grade 2 (19.3 vs 14.7 months). No significant difference was observed for median PFS.
Deng M, Li S, Wang Q, et al. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Ann Med. 2022;54(1):803-811. doi:10.1080/07853890.2022.2048416